Latest Conference Articles

September 8th 2025, 6:00pm

IASLC World Conference on Lung Cancer

Durvalumab/chemoradiation followed by consolidation durvalumab did not improve OS vs chemoradiation followed by durvalumab in stage III NSCLC.

September 8th 2025, 4:55pm

OncLive News Network: On Location at WCLC 2025

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

September 8th 2025, 4:50pm

IASLC World Conference on Lung Cancer

Taletrectinib delivered high response rates and durable benefit with manageable safety in ROS1-positive non–small cell lung cancer.

September 8th 2025, 4:10pm

IASLC World Conference on Lung Cancer

Perioperative pembrolizumab demonstrated improved mPR, pCR, EFS, and OS in patients with early-stage resectable NSCLC and any nodal status.

September 8th 2025, 4:02pm

IASLC World Conference on Lung Cancer

Adjuvant nivolumab plus chemotherapy led to a clinically meaningful reduction in relapse rates vs chemotherapy in resected NSCLC.

September 7th 2025, 9:51pm

IASLC World Conference on Lung Cancer

Ifinatamab deruxtecan was efficacious and had a manageable safety profile in patients with previously treated extensive-stage small cell lung cancer.

September 7th 2025, 7:42pm

IASLC World Conference on Lung Cancer

The brain-penetrant, TRK-sparing, ROS1-selective TKI zidesamtinib was active and safe in patients with advanced ROS1+ non–small cell lung cancer.

September 7th 2025, 6:11pm

IASLC World Conference on Lung Cancer

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

September 7th 2025, 5:55pm

IASLC World Conference on Lung Cancer

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

September 7th 2025, 5:49pm

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

September 7th 2025, 5:23pm

IASLC World Conference on Lung Cancer

Results from the ALCHEMIST trial show that adjuvant crizotinib did not improve DFS or OS vs observation in resected ALK-positive NSCLC.

September 7th 2025, 2:54pm

IASLC World Conference on Lung Cancer

Updated FLAURA2 OS data confirm osimertinib plus chemotherapy as a first-line SOC treatment in EGFR-mutated advanced NSCLC.

September 7th 2025, 2:07pm

IASLC World Conference on Lung Cancer

The addition of aumolertinib to chemotherapy improved PFS vs aumolertinib monotherapy for the treatment of patients with EGFR-mutated NSCLC.

September 7th 2025, 12:25am

IASLC World Conference on Lung Cancer

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

September 6th 2025, 9:48pm

IASLC World Conference on Lung Cancer

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

September 6th 2025, 8:03pm

IASLC World Conference on Lung Cancer

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

September 6th 2025, 5:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

September 6th 2025, 4:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

September 6th 2025, 4:30pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

September 6th 2025, 3:42pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.